HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Superficial femoral artery TASC D Registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia.

AbstractAIM:
Single center observational study analyzing the primary patency rate and freedom from target lesions revascularization rate of the Pulsar-18 nitinol stent after recanalization of long superficial femoral artery (SFA) occlusions (TASC D) in 22 patients with critical limb ischemia (CLI).
METHODS:
Between 1/2011 and 7/2011, 22 consecutive patients (9 male, 13 female) with chronic total occlusions (CTO) of the femoro-popliteal arteries presenting with CLI (17 patients with Rutherford 4 score, and 5 patients with Rutherford 5 score) were enrolled and successfully recanalized using the Pulsar-18 self-expanding (SE) nitinol stent (BIOTRONIK AG, Buelach, Switzerland). Primary patency at 12 months was defined as no binary restenosis (>50%) on Duplex ultrasound (PSVR<2.5) and respectively no target lesion revascularization performed within 12 months. The average lesion length of the treated femoro-popliteal segment was 315 mm. Performing spot stenting average stent length in all patients was 245 mm (minimal 215 mm, maximal 315 mm).
RESULTS:
Technical success, with establishing an antegrade straight line flow to the foot through a reopened SFA, was achieved in all 22 patients. Subintimal and intraluminal recanalization techniques were used. Two patients with Rutherford 5 score had a minor amputation shortly after the recanalization procedure. All other patients had a complete wound healing of their lesions during a 6 month follow-up. After 12 month follow-up the primary patency rate of the Pulsar-18 SE nitinol stent was 77% with a per protocol restenosis in 5 of 22 patients. Seventeen patients showed a walking capacity on treadmill test >300 meters (Rutherford II). Two patients with a documented restenosis were Rutherford, these patients were treated conservatively. Three patients with restenosis and a Rutherford III score were scheduled for an endovascular target lesion revascularization leading to a freedom from target lesion revascularization rate of 86%.
CONCLUSION:
Endovascular intervention of long SFA occlusions using subintimal or intraluminal recanalization technique with implantation of the Pulsar-18 SE nitinol stent in CLI patients is safe and clinically effective with a primary patency rate after 12 months of 77% and a freedom from target lesion revascularization rate of 86%.
AuthorsM Lichtenberg, W Stahlhoff, D Boese
JournalThe Journal of cardiovascular surgery (J Cardiovasc Surg (Torino)) Vol. 54 Issue 4 Pg. 433-9 (Aug 2013) ISSN: 1827-191X [Electronic] Italy
PMID24013531 (Publication Type: Journal Article)
Chemical References
  • Alloys
  • nitinol
Topics
  • Aged
  • Alloys
  • Amputation, Surgical
  • Angioplasty, Balloon (adverse effects, instrumentation)
  • Chronic Disease
  • Constriction, Pathologic
  • Critical Illness
  • Exercise Test
  • Exercise Tolerance
  • Female
  • Femoral Artery (diagnostic imaging, physiopathology)
  • Germany
  • Humans
  • Ischemia (diagnosis, physiopathology, therapy)
  • Kaplan-Meier Estimate
  • Limb Salvage
  • Lower Extremity (blood supply)
  • Male
  • Peripheral Arterial Disease (diagnosis, physiopathology, therapy)
  • Predictive Value of Tests
  • Prosthesis Design
  • Recovery of Function
  • Registries
  • Stents
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Doppler, Duplex
  • Vascular Patency
  • Wound Healing

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: